FDA Approves Autoinjector for Lerodalcibep-Liga, Updates LDL-C Indication

The FDA has approved an autoinjector for lerodalcibep-liga (Lerochol), a PCSK9 inhibitor for adults with high LDL-C. This new self-administered device offers convenience, as it does not require refrigeration for up to 90 days. The approval also clarifies the drug's indication, emphasizing its role in reducing major adverse cardiovascular events.